Currently, there are 69.11M common shares owned by the public and among those 68.45M shares have been available to trade.
The company’s stock has a 5-day price change of -5.78% and -41.13% over the past three months. BNGO shares are trading -66.98% year to date (YTD), with the 12-month market performance down to -89.33% lower. It has a 12-month low price of $0.52 and touched a high of $6.76 over the same period. BNGO has an average intraday trading volume of 1.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.10%, -29.03%, and -53.73% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bionano Genomics Inc (NASDAQ: BNGO) shares accounts for 7.11% of the company’s 69.11M shares outstanding.
It has a market capitalization of $43.12M and a beta (3y monthly) value of 2.40. The earnings-per-share (ttm) stands at -$6.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.23% over the week and 10.02% over the month.
Earnings per share for the fiscal year are expected to increase by 74.51%, and 35.28% over the next financial year.
Looking at the support for the BNGO, a number of firms have released research notes about the stock. Scotiabank stated their Sector Outperform rating for the stock in a research note on January 05, 2023, with the firm’s price target at $4. BTIG Research coverage for the Bionano Genomics Inc (BNGO) stock in a research note released on December 12, 2022 offered a Buy rating with a price target of $3.50. Oppenheimer was of a view on July 18, 2022 that the stock is Outperform, while BTIG Research gave the stock Buy rating on June 16, 2021, issuing a price target of $10. Ladenburg Thalmann on their part issued Buy rating on September 24, 2020.
